Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis by Ogdie, A, Gladman, DD, Coates, LC, Pournara, E, Parikh, B, Mease, PJ

Magnetic resonance imaging characteristics in patients with psoriatic arthritis and axial manifestations from the MAXIMISE cohort by Baraliakos, X, Pournara, E, Coates, LC, Navarro-Compán, V, Blanco, R, O’Brien, E, Schulz, B, Landewe, R

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial by Baraliakos, X, Pournara, E, Gossec, L, Mease, P, White, R, O’Brien, E, Schulz, B, Marzo Ortega, H, Coates, LC

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis by Reich, K, Baraliakos, X, Coates, LC, Elewski, B, Bao, W, Kasparek, T, Gaillez, C, Pournara, E, Aassi, M, Perella, C, Gottlieb, AB

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial by Baraliakos, X, Gossec, L, Pournara, E, Jeka, S, Varela, AM, D’Angelo, S, Schulz, B, Rissler, M, Nagar, K, Perella, C, Coates, LC

Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial by Baraliakos, X, Gossec, L, Pournara, E, Jeka, S, Blanco, R, D'Angelo, S, Schett, G, Schulz, B, Rissler, M, Whyms, D, Perella, C, Coates, LC

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis by Pournara, E, Kormaksson, M, Nash, P, Ritchlin, CT, Kirkham, BW, Ligozio, G, Pricop, L, Ogdie, A, Coates, LC, Schett, G, McInnes, IB